Tyra Bioscience (TYRA)
Raymond James analyst Christopher Raymond maintained a Buy rating on Tyra Bioscience on July 17. The company’s shares closed last Friday at $32.13.
According to TipRanks.com, Raymond is a 3-star analyst with an average return of 2.5% and a 45.4% success rate. Raymond covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Biohaven Ltd., and Climb Bio.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tyra Bioscience with a $49.88 average price target, a 60.2% upside from current levels. In a report issued on July 9, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
